Rehm Jürgen, Room Robin, van den Brink Wim, Kraus Ludwig
ISF-Addiction Research Institute, Konradstr. 32, CH 8031 Zurich, Switzerland.
Eur Neuropsychopharmacol. 2005 Aug;15(4):389-97. doi: 10.1016/j.euroneuro.2005.04.004.
To estimate the prevalence of drug use disorders in the European Union and Norway.
Based on a systematic literature search and an expert survey, publications after 1990 on prevalence of drug use disorders (DUD, defined as drug dependence and drug abuse or harmful use) in EU countries and Norway were reviewed. The search included both direct estimations based on general population surveys using the DSM-IIIR, DSM-IV, or ICD-10 definitions of DUD; and indirect estimates based on other epidemiological methods, such as multiplier procedures based on treatment or legal data and capture-recapture techniques. The indirect methods did not use diagnostic criteria, but criteria based on duration and pattern of use, labelled as problematic drug use as a meaningful approximation.
The majority of DUD as estimated from direct methods using general population surveys were cannabis use disorders, usually not included in indirect estimates. The prevalence of thus defined disorders can be as high as 3%. For disorders other than cannabis use disorders (i.e. opioid, cocaine and amphetamine use disorders), indirect estimates of prevalence were consistently higher than those based on direct estimates, and ranged between 0.3% and 0.9% in European Union countries and Norway. Men have higher prevalence rates of DUD than women, but the difference was much less pronounced in general population surveys. Younger age (18-25 years) is the age group with the highest estimates.
General population surveys typically result in a serious underestimation of the prevalence of DUD other than cannabis use disorders, because many people with DUD are not reached by these surveys (hidden populations). Based on the more valid indirect estimates, it is concluded that problem drug use constitutes a relatively high burden of disease and social problems in Europe.
评估欧盟及挪威药物使用障碍的患病率。
基于系统的文献检索和专家调查,对1990年后关于欧盟国家及挪威药物使用障碍(定义为药物依赖、药物滥用或有害使用)患病率的出版物进行了综述。检索包括基于使用《精神疾病诊断与统计手册》第三版修订本(DSM-IIIR)、《精神疾病诊断与统计手册》第四版(DSM-IV)或国际疾病分类第十版(ICD-10)中药物使用障碍定义的一般人群调查的直接估计;以及基于其他流行病学方法的间接估计,如基于治疗或法律数据的乘数程序和捕获再捕获技术。间接方法未使用诊断标准,而是基于使用持续时间和模式的标准,标记为有问题的药物使用作为一种有意义的近似值。
使用一般人群调查的直接方法估计的大多数药物使用障碍是大麻使用障碍,通常不包括在间接估计中。如此定义的障碍患病率可高达3%。对于除大麻使用障碍之外的其他障碍(即阿片类、可卡因和苯丙胺使用障碍),间接估计的患病率始终高于基于直接估计的患病率,在欧盟国家和挪威介于0.3%至0.9%之间。男性药物使用障碍的患病率高于女性,但在一般人群调查中差异不太明显。年龄较小(18 - 25岁)是估计患病率最高的年龄组。
一般人群调查通常会严重低估除大麻使用障碍之外的药物使用障碍的患病率,因为这些调查无法涵盖许多有药物使用障碍的人(隐藏人群)。基于更有效的间接估计,可以得出结论,有问题的药物使用在欧洲构成了相对较高的疾病负担和社会问题。